Sam Parker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sam Parker has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Svetlana Mastitskaya
Department of Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
3 shared publications Aidan Marsh
2 shared publications- Alex Mortimer
Southmead Hospital, Bristol NHS Foundation Trust, Bristol BS10 5NB, UK
2 shared publications - Aravind V. Ramesh
Bristol Veterinary School, University of Bristol, Bristol, UK
2 shared publications Lucy Holmes
2 shared publications- Mario Teo
Department of Neurosurgery, Bristol Institute of Clinical Neuroscience, Southmead Hospital, North Bristol NHS Trust, United Kingdom (M.T.).
2 shared publications
Latest Publications
- Open Access
Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review
Objective: The objective of this scoping review is to understand the extent and type of evidence in relation to the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection in aneurysmal subarachnoid haemorrhage (aSAH). Introduction: The individual and societal costs of aSAH remain high. Effective neuroprotection would reduce morbidity and mortality but there are uncertainties around both established and emerging therapies. GLP-1RA show promise as neuroprotective drugs in other forms of acute and chronic brain injury and could be repurposed for aSAH. Inclusion criteria: Animal and human studies of the use of GLP-1RA for aSAH will be included. Key exclusions are traumatic or non-aneurysmal subarachnoid haemorrhage, or the use of multi-agonist drugs. Methods: Searches were conducted in Embase (Ovid), Medline (Ovid), Cochrane Central Register of Controlled Trials (Wiley) and the World Health Organisation’s International Clinical Trials Registry Platform on 13th June 2025 with no limits applied. Screening and data extraction was performed by two independent reviewers. Results: After de-duplication 593 records were screened, 50 selected for full text review and 5 included in this review. GLP-1R were shown to be highly expressed in neurones and microvascular endothelial cells after aSAH. Administration of GLP-1RAs to rats affected by aSAH improved functional recovery. Furthermore, aSAH was reported to increase cerebral hemisphere oedema, blood-brain barrier permeability, cell death and inflammation, all of which were reversed by GLP-1RA treatment. Murine studies highlight potential mechanisms for these beneficial effects including inhibition of ferroptosis, downregulation of apoptosis, and upregulation of SIRT1 pathways. A human observational studies shows a correlation between higher SIRT1 levels and better neurological outcomes. Conclusion: The limited available evidence suggests a potential neuroprotective role for GLP-1RAs after aSAH. There is a need for extensive further research to determine the efficacy and safety of GLP1-RAs for neuroprotection in aSAH.
Open AccessGlucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review
Objective: The objective of this scoping review is to understand the extent and type of evidence in relation to the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection in aneurysmal subarachnoid haemorrhage (aSAH). Introduction: The individual and societal costs of aSAH remain high. Effective neuroprotection would reduce morbidity and mortality but there are uncertainties around both established and emerging therapies. GLP-1RA show promise as neuroprotective drugs in other forms of acute and chronic brain injury and could be repurposed for aSAH. Inclusion criteria: Animal and human studies of the use of GLP-1RA for aSAH will be included. Key exclusions are traumatic or non-aneurysmal subarachnoid haemorrhage, or the use of multi-agonist drugs. Methods: Searches were conducted in Embase (Ovid), Medline (Ovid), Cochrane Central Register of Controlled Trials (Wiley) and the World Health Organisation’s International Clinical Trials Registry Platform on 13th June 2025 with no limits applied. Screening and data extraction was performed by two independent reviewers. Results: After de-duplication 593 records were screened, 50 selected for full text review and 5 included in this review. GLP-1R were shown to be highly expressed in neurones and microvascular endothelial cells after aSAH. Administration of GLP-1RAs to rats affected by aSAH improved functional recovery. Furthermore, aSAH was reported to increase cerebral hemisphere oedema, blood-brain barrier permeability, cell death and inflammation, all of which were reversed by GLP-1RA treatment. Murine studies highlight potential mechanisms for these beneficial effects including inhibition of ferroptosis, downregulation of apoptosis, and upregulation of SIRT1 pathways. A human observational studies shows a correlation between higher SIRT1 levels and better neurological outcomes. Conclusion: The limited available evidence suggests a potential neuroprotective role for GLP-1RAs after aSAH. There is a need for extensive further research to determine the efficacy and safety of GLP1-RAs for neuroprotection in aSAH.
- Open Access
- 5 May 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (4) , 1646-1681
The causative role of amyloidosis in the cardiac complications of Alzheimer's disease: a comprehensive systematic review
Alzheimer's disease (AD), the leading cause of dementia, is characterised by cerebral amyloid‐beta (Aβ) and tau deposition, impairing cognition. While cardiovascular diseases exacerbate AD, the reverse association is underappreciated. This systematic review examined clinical and experimental studies that explored the cardiogenic dementia hypothesis and mechanisms by which amyloidosis in AD contributes to cardiovascular complications. A review of PubMed, Ovid Embase/Medline, and CINAHL conducted in August 2024 identified 252 studies meeting the selection criteria. Evidence links cerebral hypoperfusion from cardiac arrest, heart failure, or orthostatic hypotension to AD pathology, while atherosclerosis and hypertension drive neurodegeneration and cerebral amyloidosis. Vascular scoring tools, such as the Framingham Risk Score, may predict an individual's risk of cognitive impairment. Cardiac amyloidosis correlated with ECG abnormalities, aortic valve calcification, cardiomyopathy and atrial fibrillation. Aβ peptides and AD‐related genes exacerbate cardiac fibrosis, negative inotropy and heart rate changes, reduce nitric oxide‐mediated vasodilatation, and increase oxidative stress. Preclinical studies revealed that β‐secretase impacts cardiac repolarisation by interfering with delayed rectifier current, although clinical evidence for arrhythmogenesis remains conflicting. AD‐related autonomic dysregulation, particularly parasympathetic dysfunction, predisposes to arrhythmias. Additionally, hypercortisolaemia observed in AD has been associated with increased arterial stiffness. Diminished melatonin levels in AD were also linked to endothelial and mitochondrial dysfunction. This review enhances our understanding of how cerebral and cardiac amyloidosis, autonomic dysfunction, and endocrinopathy contribute to cardiac complications in AD, paving the way for research into targeted therapies. image
- 5 May 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (4) , 1646-1681
Open AccessThe causative role of amyloidosis in the cardiac complications of Alzheimer's disease: a comprehensive systematic review
Alzheimer's disease (AD), the leading cause of dementia, is characterised by cerebral amyloid‐beta (Aβ) and tau deposition, impairing cognition. While cardiovascular diseases exacerbate AD, the reverse association is underappreciated. This systematic review examined clinical and experimental studies that explored the cardiogenic dementia hypothesis and mechanisms by which amyloidosis in AD contributes to cardiovascular complications. A review of PubMed, Ovid Embase/Medline, and CINAHL conducted in August 2024 identified 252 studies meeting the selection criteria. Evidence links cerebral hypoperfusion from cardiac arrest, heart failure, or orthostatic hypotension to AD pathology, while atherosclerosis and hypertension drive neurodegeneration and cerebral amyloidosis. Vascular scoring tools, such as the Framingham Risk Score, may predict an individual's risk of cognitive impairment. Cardiac amyloidosis correlated with ECG abnormalities, aortic valve calcification, cardiomyopathy and atrial fibrillation. Aβ peptides and AD‐related genes exacerbate cardiac fibrosis, negative inotropy and heart rate changes, reduce nitric oxide‐mediated vasodilatation, and increase oxidative stress. Preclinical studies revealed that β‐secretase impacts cardiac repolarisation by interfering with delayed rectifier current, although clinical evidence for arrhythmogenesis remains conflicting. AD‐related autonomic dysregulation, particularly parasympathetic dysfunction, predisposes to arrhythmias. Additionally, hypercortisolaemia observed in AD has been associated with increased arterial stiffness. Diminished melatonin levels in AD were also linked to endothelial and mitochondrial dysfunction. This review enhances our understanding of how cerebral and cardiac amyloidosis, autonomic dysfunction, and endocrinopathy contribute to cardiac complications in AD, paving the way for research into targeted therapies. image
- Open Access
Glucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review protocol
Objective The objective of this scoping review is to understand the extent and type of evidence in relation to the use of glucagon-like peptide-1 receptor agonists (GLP1-RA) for neuroprotection in aneurysmal subarachnoid haemorrhage (aSAH). Introduction The individual and societal costs of aSAH remain high. Effective neuroprotection would reduce morbidity and mortality but there are uncertainties around both established and emerging therapies. GLP1-RA show promise as neuroprotective drugs in other forms of acute and chronic brain injury and could be repurposed for aSAH. Inclusion criteria Animal and human studies of the use of GLP1-RA for aSAH will be included. Key exclusions are traumatic or non-aneurysmal subarachnoid haemorrhage, or the use of multi-agonist drugs. Methods Searches will conducted in Embase (Ovid), Medline (Ovid), Cochrane Central Register of Controlled Trials (Wiley) and the World Health Organisation’s International Clinical Trials Registry Platform with no limits applied. Studies for data extraction will be identified by two independent reviewers after screening of titles and abstracts then full text review of potentially relevant articles against inclusion criteria. Data will be extracted by two independent reviewers using a charting tool based on the Joanna Briggs Institute template. A narrative review and summary of findings will be presented.
Open AccessGlucagon-like peptide-1 receptor agonists (GLP-1RA) for neuroprotection following aneurysmal subarachnoid haemorrhage (aSAH): a scoping review protocol
Objective The objective of this scoping review is to understand the extent and type of evidence in relation to the use of glucagon-like peptide-1 receptor agonists (GLP1-RA) for neuroprotection in aneurysmal subarachnoid haemorrhage (aSAH). Introduction The individual and societal costs of aSAH remain high. Effective neuroprotection would reduce morbidity and mortality but there are uncertainties around both established and emerging therapies. GLP1-RA show promise as neuroprotective drugs in other forms of acute and chronic brain injury and could be repurposed for aSAH. Inclusion criteria Animal and human studies of the use of GLP1-RA for aSAH will be included. Key exclusions are traumatic or non-aneurysmal subarachnoid haemorrhage, or the use of multi-agonist drugs. Methods Searches will conducted in Embase (Ovid), Medline (Ovid), Cochrane Central Register of Controlled Trials (Wiley) and the World Health Organisation’s International Clinical Trials Registry Platform with no limits applied. Studies for data extraction will be identified by two independent reviewers after screening of titles and abstracts then full text review of potentially relevant articles against inclusion criteria. Data will be extracted by two independent reviewers using a charting tool based on the Joanna Briggs Institute template. A narrative review and summary of findings will be presented.